Accepted Manuscript

Myoglobinuria in two patients with Duchenne Muscular Dystrophy after treatment with zoledronate: a case-report and call for caution

Anton Ivanyuk MD , Nuria García Segarra MD , Thierry Buclin MD , Andrea Klein MD , David Jacquier MD , Christopher J. Newman MD , Clemens Bloetzer MD

PII: \$0960-8966(17)31486-4


DOI: https://doi.org/10.1016/j.nmd.2018.08.004

Reference: NMD 3597

To appear in: Neuromuscular Disorders

Received date: 29 December 2017

Revised date: 7 June 2018 Accepted date: 6 August 2018



Please cite this article as: Anton Ivanyuk MD, Nuria García Segarra MD, Thierry Buclin MD, Andrea Klein MD, David Jacquier MD, Christopher J. Newman MD, Clemens Bloetzer MD, Myoglobinuria in two patients with Duchenne Muscular Dystrophy after treatment with zoledronate: a case-report and call for caution, *Neuromuscular Disorders* (2018), doi: https://doi.org/10.1016/j.nmd.2018.08.004

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Highlights

- Bisphosphonates are increasingly used in children with DMD
- Bisphosphonate-induced rhabdomyolysis has not previously been described in children
- We observed two pediatric cases of apparent rhabdomyolysis after zoledronate infusion
- Hypophosphatemia or myotoxicity are likely explanations for this possible side effect
- Nitrogen-containing bisphosphonates are likely to be concerned by this hazard

Download English Version:

https://daneshyari.com/en/article/11014764

Download Persian Version:

https://daneshyari.com/article/11014764

<u>Daneshyari.com</u>